Leadless Pacemakers: NICE Guidance & Benefits
- The National Institute for Health and Care Excellence (NICE) has issued draft guidance supporting the use of leadless cardiac pacemakers for patients with bradyarrhythmias requiring single-chamber pacing.This recommendation...
- The review considered a randomized controlled trial, systematic reviews, registry studies, and prospective and retrospective studies.
- Anastasia Chalkidou, HealthTech program director at NICE, said the evidence indicates that leadless pacemakers can effectively regulate heart rhythm while lowering the risk of complications frequently enough associated...
NICE now recommends leadless pacemakers for single-chamber bradyarrhythmias, offering a notable advancement in cardiac care. This decision, based on extensive research involving over a million patients, highlights the benefits of reduced infection risk compared to traditional pacemakers. The guidance from NICE, meticulously reviewed and analyzed, champions the efficiency of leadless pacemakers in regulating heart rhythm and improving patient well-being. Explore how these innovative devices minimize complications and enhance the quality of life for those affected by bradyarrhythmias.As News Directory 3 reports, further research will focus on dual-chamber systems. Discover what’s next in this evolving field.
NICE Recommends Leadless Pacemakers for Single-Chamber Bradyarrhythmias
Updated June 25, 2025
The National Institute for Health and Care Excellence (NICE) has issued draft guidance supporting the use of leadless cardiac pacemakers for patients with bradyarrhythmias requiring single-chamber pacing.This recommendation stems from a thorough review of evidence, including multiple studies involving over one million patients.
The review considered a randomized controlled trial, systematic reviews, registry studies, and prospective and retrospective studies. NICE resolute that leadless pacemakers effectively regulate heart rhythm and improve patient quality of life. A key advantage over traditional transvenous pacemakers (TVPs) is the elimination of a chest incision, which reduces the risk of infection and other complications.
Dr. Anastasia Chalkidou, HealthTech program director at NICE, said the evidence indicates that leadless pacemakers can effectively regulate heart rhythm while lowering the risk of complications frequently enough associated with traditional pacemakers, especially infections and lead-related problems.
Bradyarrhythmias, affecting roughly 1 in 1,000 people, are commonly treated with TVPs, which involve a subcutaneous pacemaker box and leads connected to the heart. Single-chamber leadless pacemakers are typically inserted percutaneously thru a vein and guided into the right ventricle.
Dual-chamber systems, involving two devices placed in both the right atrium and right ventricle, are still under evaluation. NICE noted that TVPs carry risks, including lead failure and generator-related issues.Leadless pacemaker implantation may be preferable for patients with a history of device infection, endocarditis, immunosuppression, limited vascular access, or high infection risk.
What’s next
While supporting leadless pacemakers for single-chamber pacing, NICE emphasizes the need for further research before broader endorsement. This includes studies on patient selection, implantation sites, clinical outcomes, and the long-term durability of leadless devices. The draft guidance is open for public comment until July 23, 2025, and the advisory committee will reconvene Sept. 11, 2025, to finalize recommendations, according to Professor Tom Clutton-Brock, chair of NICE’s interventional procedures advisory committee.